Ms. Jenene Thomas reports
AETERNA ZENTARIS ANNOUNCES $7.0 MILLION REGISTERED DIRECT OFFERING PRICED AT-THE-MARKET
Aeterna Zentaris Inc. has entered into a securities purchase agreement with several institutional investors in the United States providing for the sale and issuance of approximately 12,427,876 common shares at a purchase price of 56.325 cents per common share in a registered direct offering priced at the market under Nasdaq rules. The offering is expected to result in gross proceeds to Aeterna Zentaris of approximately $7.0-million.
Aeterna Zentaris will also issue to the purchasers unregistered warrants to purchase up to an aggregate of 9,320,907 common shares. The warrants will be exercisable for a period of 5-1/2 years, exercisable immediately following the issuance date, and have an exercise price of 47 cents per common share.
H.C. Wainwright & Co. is acting as the exclusive placement agent for the offering.
The company intends to use the net proceeds of this offering for general corporate purposes, which include, among other purposes, the financing of a pediatric clinical trial in the European Union and United States for Macrilen (macimorelin), the investigation of further therapeutic uses of macimorelin, and the expansion of pipeline development activities.
The registered direct offering and concurrent private placement are expected to close on or about Aug. 5, 2020, subject to the satisfaction of customary closing conditions.
The common shares described herein (but not the warrants or the common shares underlying the warrants) are being offered by Aeterna Zentaris pursuant to a shelf registration statement on Form F-3 (file No. 333-232935), which was previously declared effective by the U.S. Securities and Exchange Commission (SEC) on Aug. 15, 2019. Such common shares may be offered only by means of a prospectus, including a prospectus supplement, forming a part of the effective registration statement.
A prospectus supplement relating to the common shares will be filed by Aeterna with the SEC. When filed with the SEC, copies of the prospectus supplement and the accompanying prospectus relating to the registered direct offering may be obtained at the SEC's website. Electronic copies of the prospectus supplement and accompanying prospectus relating to the registered direct offering may also be obtained by contacting H.C. Wainwright & Co., 430 Park Ave., third floor, New York, N.Y., 10022, by telephone at 646-975-6996 or by e-mail at
The warrants described herein were offered in a private placement pursuant to an applicable exemption from the registration requirements of the Securities Act of 1933, as amended, and, along with the common shares issuable upon their exercise, have not been registered under the act, and may not be offered or sold in the United States absent registration with the SEC or an applicable exemption from such registration requirements.
About Aeterna Zentaris Inc.
Aeterna Zentaris is a specialty biopharmaceutical company, commercializing and developing therapeutics and diagnostic tests. The company's lead product, Macrilen (macimorelin), is the first and only U.S. Food and Drug Administration- and European Commission-approved oral test indicated for the diagnosis of adult growth hormone deficiency (AGHD). Macrilen is currently marketed in the United States through a licence agreement with Novo Nordisk, and Aeterna Zentaris receives double-digit royalties on sales. Aeterna Zentaris owns all rights to macimorelin outside of the U.S. and Canada.
We seek Safe Harbor.
© 2021 Canjex Publishing Ltd. All rights reserved.